[The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial Fibrillation and Chronic Kidney Disease].

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Kardiologiia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 28290837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.

  2016cited by this paper
• Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.

  2016cited by this paper
• Chronic Kidney Disease and the Risk of New-Onset Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies

  2016cited by this paper
• Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study

  2016cited by this paper
• Atrial Fibrillation and Risk of ESRD in Adults with CKD.

  2016cited by this paper
• Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review.

  2016cited by this paper
• US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States.

  2016cited by this paper
• Vitamin-K-Dependent Protection of the Renal Microvasculature: Histopathological Studies in Normal and Diseased Kidneys

  2016cited by this paper
• Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.

  2016cited by this paper
• Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis

  2016cited by this paper
• Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis.

  2016cited by this paper
• Atrial fibrillation and chronic kidney disease: struggling through thick and thin.

  2016cited by this paper
• Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.

  2015cited by this paper
• Increased Vascular Calcification in Patients Receiving Warfarin

  2015cited by this paper
• Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.

  2015cited by this paper
• Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.

  2015cited by this paper
• The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study

  2015cited by this paper
• Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.

  2015cited by this paper
• Dose-finding study of rivaroxaban in hemodialysis patients.

  2015cited by this paper
• Dabigatran treatment simulation in patients undergoing maintenance haemodialysis

  2015cited by this paper
• The importance of vitamin K monitoring with warfarin (Coumadin) use in chronic kidney disease patients.

  2015cited by this paper
• Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists

  2015cited by this paper
• Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis

  2014cited by this paper
• Risk of stroke in long-term dialysis patients compared with the general population.

  2014cited by this paper
• Incident Atrial Fibrillation and Risk of Death in Adults With Chronic Kidney Disease

  2014cited by this paper
• Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

  2014cited by this paper
• Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.

  2014cited by this paper
• Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation.

  2014cited by this paper
• Apixaban Use Among Patients With Severe Renal Impairment

  2014cited by this paper
• Consistency of safety profile of new oral anticoagulants in patients with renal failure

  2014cited by this paper
• Research Progress of Warfarin-associated Vascular Calcification and Its Possible Therapy

  2014cited by this paper
• Stroke and cerebrovascular diseases in patients with chronic kidney disease.

  2014cited by this paper
• Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.

  2014cited by this paper
• Evaluation of Warfarin Dose Requirements in Patients with Chronic Kidney Disease and End‐Stage Renal Disease

  2014cited by this paper
• 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation.

  2014cited by this paper
• Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.

  2014cited by this paper
• Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis

  2013cited by this paper
• Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.

  2013cited by this paper
• Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease.

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.

  2013cited by this paper
• The role of vitamin K in soft-tissue calcification.

  2012cited by this paper
• Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis.

  2012cited by this paper
• Vitamin K status and vascular calcification: evidence from observational and clinical studies.

  2012cited by this paper
• The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice

  2012cited by this paper
• Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

  2012cited by this paper
• Stroke and bleeding in atrial fibrillation with chronic kidney disease.

  2012cited by this paper
• Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.

  2011cited by this paper
• Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs

  2011cited by this paper
• Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation.

  2011cited by this paper
• Evolution of Treatment Strategies for Calciphylaxis

  2011cited by this paper
• Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

  2010cited by this paper
• Vitamins K and D status in stages 3-5 chronic kidney disease.

  2010cited by this paper
• Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.

  2010cited by this paper
• Low glomerular filtration rate and risk of stroke: meta-analysis

  2010cited by this paper
• The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report.

  2010cited by this paper
• Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).

  2010cited by this paper
• Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Matrix Gla-protein: The calcification inhibitor in need of vitamin K

  2008cited by this paper
• Vitamin K-dependent proteins, warfarin, and vascular calcification.

  2008cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates.

  2007cited by this paper
• Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy

  2004cited by this paper

• No citing papers are available for this paper.